MedWatch

Leo Pharma achieves French milestone

Denmark-based Leo Pharma has won approval from French medicines authorities of a new indication for one of the company’s biggest products . The Danes expect additional markets to follow suit in the wake of planned studies.

For years, Innohep has been the cornerstone of Leo Pharma’s product portfolio and, although skin diseases is the professed main area of the company, the size of the product has helped create a sizeable business in the anticoagulant area, to which Innohep belongs, says EVP of Global Sales & Marketing, Lars Olsen.

For a number of years, Leo Pharma has been marketing the injection drug, Innohep, for prophylactic blood clots as well as blood clots in the legs and lungs, but with approval of a new indication in France the market potential could be significantly expanded.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

CHMP blåstempler ni nye lægemidler i maj

Den europæiske lægemiddelkomite, CHMP, har på dets møde i maj indstillet ni nye lægemidler til godkendelse samt anbefalet, at seks midler kan tages i brug på nye måder. To midler afvist.

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier